CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

Abstract Introduction Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cogni...

Full description

Saved in:
Bibliographic Details
Main Authors: Nathan Herrmann, Zahinoor Ismail, Rhonda Collins, Philippe Desmarais, Zahra Goodarzi, Alexandre Henri‐Bhargava, Andrea Iaboni, Julia Kirkham, Fadi Massoud, Andrea Moser, James Silvius, Jennifer Watt, Dallas Seitz
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
cholinesterase inhibitor
memantine
cognitive enhancer
dementia
deprescribing
discontinuation
Online Access:https://doi.org/10.1002/trc2.12099
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.12099

Similar Items